Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
Search jobs 11-May-2021 Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer Data from the first positive Phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalized healthcare exploring tumor agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualized treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest hematology portfolio in industry
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held June 4-8, 2021. A tot
(2)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq
(atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1-stained tumor-infiltrating immune cells covering =5 percent of the tumor area) as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Today s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts thou